These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 27357182)

  • 21. A randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of anagliptin in drug-naïve patients with type 2 diabetes.
    Yang HK; Min KW; Park SW; Chung CH; Park KS; Choi SH; Song KH; Kim DM; Lee MK; Sung YA; Baik SH; Kim IJ; Cha BS; Park JH; Ahn YB; Lee IK; Yoo SJ; Kim J; Park IeB; Park TS; Yoon KH
    Endocr J; 2015; 62(5):449-62. PubMed ID: 25819061
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients.
    Ayaori M; Iwakami N; Uto-Kondo H; Sato H; Sasaki M; Komatsu T; Iizuka M; Takiguchi S; Yakushiji E; Nakaya K; Yogo M; Ogura M; Takase B; Murakami T; Ikewaki K
    J Am Heart Assoc; 2013 Jan; 2(1):e003277. PubMed ID: 23525426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients.
    Shao SC; Chang KC; Lin SJ; Chien RN; Hung MJ; Chan YY; Kao Yang YH; Lai EC
    Cardiovasc Diabetol; 2020 Feb; 19(1):17. PubMed ID: 32050968
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial.
    Santamarina M; Carlson CJ
    BMC Cardiovasc Disord; 2019 Mar; 19(1):60. PubMed ID: 30876392
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of dipeptidyl peptidase-4 inhibitors on cardiac and endothelial function in type 2 diabetes mellitus: A pilot study.
    Leung M; Leung DY; Wong VW
    Diab Vasc Dis Res; 2016 May; 13(3):236-43. PubMed ID: 26993495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of glucose control on arterial stiffness in patients with type 2 diabetes mellitus and hypertension: An observational study.
    Chang S; Kim J; Sohn T; Son H; Lee J
    J Int Med Res; 2018 Jan; 46(1):284-292. PubMed ID: 28835148
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Dipeptidyl Peptidase-4 Inhibitor, Teneligliptin, Decreases Plasma Triglyceride-Rich Lipoprotein Remnants in Diabetic Patients with Chronic Kidney Disease Undergoing Hemodialysis.
    Homma K; Yoshizawa J; Shiina Y; Ozawa H; Igarashi M; Matsuoka T; Sasaki J; Yoshizawa M; Homma Y
    Drugs R D; 2017 Sep; 17(3):397-402. PubMed ID: 28577292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative studies of dipeptidyl peptidase 4 inhibitor vs sulphonylurea among Muslim Type 2 diabetes patients who fast in the month of Ramadan: A systematic review and meta-analysis.
    Loh HH; Yee A; Loh HS; Sukor N; Kamaruddin NA
    Prim Care Diabetes; 2016 Jun; 10(3):210-9. PubMed ID: 26392074
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.
    Kadowaki T; Kondo K
    Diabetes Obes Metab; 2014 May; 16(5):418-25. PubMed ID: 24205974
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea.
    Aso Y; Ozeki N; Terasawa T; Naruse R; Hara K; Suetsugu M; Takebayashi K; Shibazaki M; Haruki K; Morita K; Inukai T
    Transl Res; 2012 Jan; 159(1):25-31. PubMed ID: 22153807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta.
    Mizoguchi M; Tahara N; Tahara A; Nitta Y; Kodama N; Oba T; Mawatari K; Yasukawa H; Kaida H; Ishibashi M; Hayabuchi N; Harada H; Ikeda H; Yamagishi S; Imaizumi T
    JACC Cardiovasc Imaging; 2011 Oct; 4(10):1110-8. PubMed ID: 21999871
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dipeptidyl peptidase-4 inhibitor anagliptin ameliorates diabetes in mice with haploinsufficiency of glucokinase on a high-fat diet.
    Nakaya K; Kubota N; Takamoto I; Kubota T; Katsuyama H; Sato H; Tokuyama K; Hashimoto S; Goto M; Jomori T; Ueki K; Kadowaki T
    Metabolism; 2013 Jul; 62(7):939-51. PubMed ID: 23790528
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Preclinical and clinical aspects of the dipeptidyl peptidase-4 inhibitor anagliptin].
    Tsubamoto Y; Goto M
    Nihon Yakurigaku Zasshi; 2013 Jun; 141(6):339-49. PubMed ID: 23749075
    [No Abstract]   [Full Text] [Related]  

  • 34. Effects of Concomitant Administration of a Dipeptidyl Peptidase-4 Inhibitor in Japanese Patients with Type 2 Diabetes Showing Relatively Good Glycemic Control Under Treatment with a Sodium Glucose Co-Transporter 2 Inhibitor.
    Kusunoki M; Natsume Y; Miyata T; Tsutsumi K; Oshida Y
    Drug Res (Stuttg); 2018 Dec; 68(12):704-709. PubMed ID: 29966149
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of linagliptin according to patient baseline characteristics: A pooled analysis of three phase 3 trials.
    Del Prato S; Patel S; Crowe S; von Eynatten M
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):886-92. PubMed ID: 27484756
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial.
    Katakami N; Mita T; Yoshii H; Shiraiwa T; Yasuda T; Okada Y; Torimoto K; Umayahara Y; Kaneto H; Osonoi T; Yamamoto T; Kuribayashi N; Maeda K; Yokoyama H; Kosugi K; Ohtoshi K; Hayashi I; Sumitani S; Tsugawa M; Ryomoto K; Taki H; Nakamura T; Kawashima S; Sato Y; Watada H; Shimomura I;
    Cardiovasc Diabetol; 2021 Jan; 20(1):4. PubMed ID: 33397376
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus - results from an exploratory study.
    Berndt-Zipfel C; Michelson G; Dworak M; Mitry M; Löffler A; Pfützner A; Forst T
    Cardiovasc Diabetol; 2013 Apr; 12():59. PubMed ID: 23565740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial.
    Tuttolomondo A; Cirrincione A; Casuccio A; Del Cuore A; Daidone M; Di Chiara T; Di Raimondo D; Corte VD; Maida C; Simonetta I; Scaglione S; Pinto A
    Cardiovasc Diabetol; 2021 Jan; 20(1):1. PubMed ID: 33397395
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury.
    Penno G; Garofolo M; Del Prato S
    Nutr Metab Cardiovasc Dis; 2016 May; 26(5):361-73. PubMed ID: 27105869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.
    Koska J; Sands M; Burciu C; Reaven P
    Diab Vasc Dis Res; 2015 May; 12(3):154-63. PubMed ID: 25852133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.